
If approved, pemigatinib would be the first targeted therapy for patients with cholangiocarcinoma, a rare cancer that impacts the bile ducts. The disease is often diagnosed at a late or advanced stage.

If approved, pemigatinib would be the first targeted therapy for patients with cholangiocarcinoma, a rare cancer that impacts the bile ducts. The disease is often diagnosed at a late or advanced stage.

A study of college students found that better sleep—specifically, higher quality, longer duration, and greater consistency of sleep—was associated with higher scores on quizzes and midterm exams.

E-cigarette manufacturer Juul is being sued by 3 school districts; virus linked as potential cause of acute flaccid myelitis; HIV prevention drugs will be available without prescription in California

More than 2 years after the FDA derailed the trajectory of its novel treatment system for type 2 diabetes (T2D), Intarcia Therapeutics today announced that regulators have accepted a resubmitted new drug application for the mini pump that delivers a continuous dose of exenatide.

JAMA on Tuesday retracted and republished a 2018 study about chronic obstructive pulmonary disease (COPD) after the discovery of a programming error in the statistical analysis. The subsequent complete reanalysis by the authors showed that the intervention that was studied showed harm, rather than benefit, to patients.

Noninvasive transcranial magnetic stimulation (TMS) may help improve cognitive performance in patients with Parkinson disease (PD) and mild cognitive impairment, according to a recent study.

Although minimal residual disease (MRD) is increasingly being used to predict treatment outcomes and as a surrogate marker of progression-free survival, there remains controversy over whether it is ready to be used in treatment decision making.

Use of wrist-worn step trackers were shown to accurately estimate exercise capacity and determine the health status of patients with COPD and cardiovascular diseases, based off research presented at the 2019 European Respiratory Society Congress.


A study last year pointed to empagliflozin as the best choice for patients who have type 2 diabetes and non-alcoholic fatty liver disease.

US Supreme Court to hear appeals for abortion access in Louisiana; the Trump administration proposes to suspend visas for uninsured immigrants; a temporary ban on flavored vaping products in Oregon.

The mechanism studied affects a broad range of physiological responses and is now the focus of intense study by the pharmaceutical industry.

The 2019 Kaiser Family Foundation Employer Health Benefits Survey results revealed significant rises in annual premiums, setting the context for the role of health insurance reform during the 2020 election cycle.

Pimavanserin may be an effective treatment option for patients with Parkinson disease who develop Parkinson disease psychosis, according to a recent study published by Neuropsychiatric Disease and Treatment.

The Knock Out Opioid Abuse Town Hall occurred today at the Rutgers Athletic Center, which highlighted the impact of the opioid epidemic nationwide and its increased risk among athletes.

Diagnosis of hypertension was based on guidelines updated by the American College of Cardiology and the American Heart Association in 2017.

Researchers found that people who had deep brain stimulation (DBS) for medication refractory tremor were predominantly men.

While current guidelines recommend that only women with breast cancer who have a family history or who meet clinical criteria undergo genetic testing, a new cost-effectiveness analysis suggests that genetic testing should be expanded to all women with breast cancer.

Researchers have proposed a new tool and framework involving a personalized approach for managing chronic obstructive pulmonary disease (COPD) and the use of inhaled corticosteroids.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Walmart will launch a pilot value-based care program in January 2020; Humana is positioning itself from “an insurance company with elements of healthcare to a healthcare company with elements of insurance"; efforts are paying off to get an answer from CMS about delays in bonus payments due to doctors who take part in alternative payment models (APMs).

This week, the top managed care news included Medicare cuts hospital payments over readmissions; a second-generation chimeric antigen receptor T-cell therapy shows promise; a diabetes drug is approved to prevent kidney failure for the first time.

A recent study said vacuolization can easily be determined and may be a useful biomarker to predict acute myeloid leukemia risk groups as well as early treatment response rates and survival.

President Donald Trump has issued an executive order that will protect Medicare and bolster Medicare Advantage (MA) in response to Democrats' Medicare for All proposals.


Patients with severe persistent asthma or severe COPD, with additional inclinations toward anxiety or panic disorders, exhibited an increased interest in using digital inhalers, based off 2 Health Union condition-specific surveys.

The FDA has approved Gilead’s second HIV prevention pill, Descovy, for at-risk adults and adolescents weighing at least 35 kg, excluding those who are at risk of HIV due to vaginal sex because the efficacy of Descovy has not been assessed in this population.

Minority representation in clinical studies often becomes overlooked, which can inhibit attributable research and heightened risk awareness within these subpopulations.

The findings indicate that the initiation of tuberculosis preventive therapy isoniazid during pregnancy carries greater risk than initiation of the treatment during the postpartum period.

New York Governor Andrew Cuomo said that the state is on track to meet its goal of ending the HIV/AIDS epidemic in New York by 2020; lung damage exhibited by some patients as a result of vaping resembles the damage on lungs exposed to chemical spills or harmful gases; a federal judge has ruled that a Philadelphia nonprofit’s plan to open a supervised injection drug site for drug users does not break federal law.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
